4CPS-182 Nutritional assessment of non-small-cell lung cancer patients undergoing treatment with osimertinib

<h3>Background and Importance</h3> Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a major cause of morbidity and mortality globally. At the time of diagnosis, 35% to 65% of NSCLC patients present with nutritional issues such as malnutrition, which negatively impacts prognosis, treatment response, and overall quality of life. Sarcopenia, characterised by the loss of skeletal muscle mass and strength, further complicates outcomes in cancer patients. Identifying the nutritional status and body composition of patients receiving targeted therapies like osimertinib is essential to optimise treatment and manage adverse effects. <h3>Aim and Objectives</h3> The primary aim of this study was to assess the nutritional status and body composition of NSCLC patients undergoing treatment with osimertinib, a third-generation tyrosine kinase inhibitor (TKI). Secondary objectives were to evaluate the prevalence of sarcopenia and examine the relationship between low muscle mass, malnutrition, and the occurrence of dose-limiting toxicities during treatment. <h3>Material and Methods</h3> This observational, descriptive, cross-sectional study included 25 adult NSCLC patients treated with osimertinib. Anthropometric measurements were recorded, body composition was analysed using bioelectrical impedance analysis (BIA), and muscle functionality was assessed through handgrip strength (dynamometry). Nutritional status was classified according to established diagnostic criteria. <h3>Results</h3> A total of 25 patients (60% women), with a median age of 72 (33–87) years were included. Malnutrition was identified in 36% of patients and 66.7% of patients diagnosed with malnutrition presented DLT. Sarcopenia was present in 4% of patients, 8% were classified as pre-sarcopenic, and 20% exhibited dynapenia. Patients who developed dose-limiting toxicities showed significantly lower fat-free mass and fat-free mass index, suggesting that reduced muscle mass may be associated with higher treatment-related toxicities. Although no statistically significant association was found between malnutrition and toxicities, patients with malnutrition tended to experience more adverse effects. <h3>Conclusion and Relevance</h3> These findings emphasise the importance of early and individualised nutritional interventions in NSCLC patients receiving osimertinib to enhance their nutritional status, optimise cancer treatment, and reduce dose-limiting toxicities. Future research involving larger patient cohorts and longitudinal designs is needed to validate these results and investigate the efficacy of nutritional interventions. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest